Pharmacological therapies for ARDS

Hiroaki Izumida, Seitaro Fujishima

Research output: Contribution to journalArticle

Abstract

Acute respiratory distress syndrome (ARDS) is a non-cardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg·kg-1·day -1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5 mg·kg-1·day-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.

Original languageEnglish
Pages (from-to)541-546
Number of pages6
JournalJapanese Journal of Anesthesiology
Volume62
Issue number5
Publication statusPublished - 2013 May

Fingerprint

Adult Respiratory Distress Syndrome
Pharmacology
Adrenal Cortex Hormones
Methylprednisolone
Therapeutics
Secretory Proteinase Inhibitory Proteins
Mortality
Capillary Permeability
Pulmonary Edema
Mechanical Ventilators
Sodium
Lung
Pharmaceutical Preparations

Keywords

  • Acute respiratory distress syndrome
  • Corticosteroids
  • Pharmacologic therapy

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pharmacological therapies for ARDS. / Izumida, Hiroaki; Fujishima, Seitaro.

In: Japanese Journal of Anesthesiology, Vol. 62, No. 5, 05.2013, p. 541-546.

Research output: Contribution to journalArticle

Izumida, Hiroaki ; Fujishima, Seitaro. / Pharmacological therapies for ARDS. In: Japanese Journal of Anesthesiology. 2013 ; Vol. 62, No. 5. pp. 541-546.
@article{bc9534b5f036495ab996b453cdf6fedf,
title = "Pharmacological therapies for ARDS",
abstract = "Acute respiratory distress syndrome (ARDS) is a non-cardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg·kg-1·day -1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5 mg·kg-1·day-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.",
keywords = "Acute respiratory distress syndrome, Corticosteroids, Pharmacologic therapy",
author = "Hiroaki Izumida and Seitaro Fujishima",
year = "2013",
month = "5",
language = "English",
volume = "62",
pages = "541--546",
journal = "Japanese Journal of Anesthesiology",
issn = "0021-4892",
publisher = "Kokuseido Publishing Co. Ltd",
number = "5",

}

TY - JOUR

T1 - Pharmacological therapies for ARDS

AU - Izumida, Hiroaki

AU - Fujishima, Seitaro

PY - 2013/5

Y1 - 2013/5

N2 - Acute respiratory distress syndrome (ARDS) is a non-cardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg·kg-1·day -1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5 mg·kg-1·day-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.

AB - Acute respiratory distress syndrome (ARDS) is a non-cardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg·kg-1·day -1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5 mg·kg-1·day-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.

KW - Acute respiratory distress syndrome

KW - Corticosteroids

KW - Pharmacologic therapy

UR - http://www.scopus.com/inward/record.url?scp=84878081704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878081704&partnerID=8YFLogxK

M3 - Article

C2 - 23772527

AN - SCOPUS:84878081704

VL - 62

SP - 541

EP - 546

JO - Japanese Journal of Anesthesiology

JF - Japanese Journal of Anesthesiology

SN - 0021-4892

IS - 5

ER -